Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-216763 SCHEMBL29358424 | 1.00 | GSK3B (1.00) | GSK3BGSK3ACDK4CCND1CDK2 | |
| Sb-216763 SCHEMBL29361308 | 1.00 | GSK3B (1.00) | GSK3BGSK3ACDK4CCND1CDK2 | |
| Sb-216763 SCHEMBL28496282 | 0.99 | GSK3B (0.98) | GSK3BGSK3ACDK4CCND1CDK2 | |
| SCHEMBL8163218 | 0.90 | GSK3B (0.81) | GSK3BGSK3ACDK4CCND1CDK2 | |
| SCHEMBL8154922 | 0.90 | GSK3B (0.81) | GSK3BGSK3ACDK4CCND1CDK2 | |
| SCHEMBL13523822 | 0.89 | GSK3B (0.80) | GSK3BGSK3ACDK4CCND1CDK2 | |
| SCHEMBL30319850 | 0.87 | GSK3B (1.00) | GSK3BGSK3ACDK4CCND1CDK2 | |
| SCHEMBL5682596 | 0.87 | GSK3B (1.00) | GSK3BGSK3ACDK4CCND1CDK2 | |
| SCHEMBL30319849 | 0.85 | CCNE2 (1.00) | GSK3BCDK4CCND1CDK2PRKCA | |
| SCHEMBL5686048 | 0.85 | CCNE2 (1.00) | GSK3BCDK4CCND1CDK2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 922 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102434-A1 | HIGH-PERFORMANCE MATURE INTESTINAL ORGANOID REGENERATIVE THERAPEUTIC AGENT DERIVED FROM PLURIPOTENT STEM CELLS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2026-04-16 | — | — | US | claimed |
| EP-4592382-A1 | HIGH-PERFORMANCE MATURE INTESTINAL ORGANOID REGENERATIVE THERAPEUTIC AGENT DERIVED FROM PLURIPOTENT STEM CELLS | Korea Research Institute of Bioscience and Biotechnology (KR) | 2025-07-30 | — | — | EP | claimed |
| US-20250215397-A1 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2025-07-03 | — | — | US | claimed |
| US-RE50313-E1 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2025-02-25 | — | — | US | claimed |
| US-20240269129-A1 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | THE BROAD INSTITUTE, INC. | 2024-08-15 | — | — | US | claimed |
| WO-2024063533-A1 | HIGH-PERFORMANCE MATURE INTESTINAL ORGANOID REGENERATIVE THERAPEUTIC AGENT DERIVED FROM PLURIPOTENT STEM CELLS | 한국생명공학연구원 | 2024-03-28 | — | — | WO | claimed |
| EP-3384007-B1 | IMPROVED METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) | 2024-03-27 | — | — | EP | claimed |
| US-11795436-B2 | Derivation of hepatic stem cells and mature liver cell types and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-10-24 | — | — | US | claimed |
| CN-108431209-B | Derived and mature hepatocyte types of liver stem cells and uses thereof | 新加坡科技研究局 | 2023-02-10 | — | — | CN | claimed |
| EP-3702445-B1 | NOVEL MUSCULOSKELETAL STEM CELL | CELLATOZ THERAPEUTICS INC (KR) | 2022-12-07 | — | — | EP | claimed |
| US-20070196514-A1 | Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors | UNIVERSITY OF KANSAS MEDICAL CENTER | 2007-08-23 | — | — | US | claimed |
| WO-2007086093-A2 | INHIBITORS OF CELL MIGRATION MEDIATED BY H-PRUNE-GSK-3 COMPLEX AND USES IN ANTITUMORAL THERAPY | BIO FLAG S R L (IT) | 2007-08-02 | — | — | WO | claimed |
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | WYETH | 2006-11-09 | — | — | US | claimed |
| US-20060217368-A1 | Drug for nerve regeneration | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-28 | — | — | US | claimed |
| WO-2005028678-A9 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH CORP (US) | 2006-08-31 | — | — | WO | claimed |
| EP-1645286-A1 | DRUG FOR NERVE REGENERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-12 | — | — | EP | claimed |
| EP-1636388-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | Wyeth (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005028678-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH (US) | 2005-03-31 | — | — | WO | claimed |
| EP-1140070-A1 | TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 | SMITHKLINE BEECHAM PLC (GB) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038675-A1 | TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 | SMITHKLINE BEECHAM PLC (GB) | 2000-07-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217368-A1 | Drug for nerve regeneration | GSK3A, BDNF, GSK3B | GSK3B 3/4885GSK3A 1/4885CDK4 85/4885 |
| US-20240269129-A1 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | GSK3B, GSK3A, CTNNB1 | GSK3B 1/4885GSK3A 2/4885CDK4 802/4885 |
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | BMP4, BMP2, BMP6 | GSK3B 2078/4885GSK3A 2144/4885CDK4 695/4885 |
| US-20260102434-A1 | HIGH-PERFORMANCE MATURE INTESTINAL ORGANOID REGENERATIVE THERAPEUTIC AGENT DERIVED FROM PLURIPOTENT STEM CELLS | MYLK, MYLK2, DSP | GSK3B 975/4885GSK3A 1293/4885CDK4 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.